Update on Strategic Review
11/12/2018
RNS
Completion of q16 molecular diagnostics order
06/12/2018
Liquidity Agreement and Total Voting Rights
03/12/2018
Replacement: Unsecured Debt Facility
30/11/2018
$3.0M supply agreement with Genesis Diagnostics
27/11/2018
Liquidity Agreement
01/11/2018
01/10/2018
Novacyt Half Year 2018 Results
26/09/2018
Novacyt Partners with Applied Microarrays
13/09/2018
03/09/2018
02/08/2018
Half Year Revenue Update
Revenue update to be announced on 2 August 2018
26/07/2018
Liquidity Agreement Update and Total Voting Rights
02/07/2018
Acquisition of ID Business from Omega Diagnostics
28/06/2018
Replacement – Results of Annual General Meeting
12/06/2018
Results of Annual General Meeting
Launch of New Product in Infectious Mononucleosis
05/06/2018
01/06/2018
New Unsecured Debt Facility
30/05/2018
For Investor Relations Support for the Novacyt Group, please click the button below to contact our team.